


Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031.

U.S. Patent and Trademark Office: U.S. D

#3
10S

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				<i>Patent & Trademark Office</i>		Complete if Known	
INFORMATION DISCLOSURES STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/872,698		
				Filing Date	June 1, 2001		
				First Named Inventor	Elsberry		
				Group Art Unit	3763		
				Examiner Name	Unknown		
				Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite PG. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		3,894,541		El-Shafei	07/15/1975	
		3,941,119		Corrales	03/02/1976	
		4,613,324		Ghajar	09/23/1986	
		4,670,313		Saudagar	06/02/1987	
		4,686,085		Osterholm	08/11/1987	
		4,710,181		Fuqua	12/01/1987	
		4,767,400		Miller et al.	08/30/1988	
		4,781,672		Hooven	11/01/1988	
		4,998,938		Ghajar et al.	03/12/1991	
		5,169,387		Kronner	12/08/1992	
		5,180,387		Ghajar et al.	01/19/1993	
		5,192,753		McGeer et al.	03/09/1993	
		5,385,541		Kirsch et al.	01/31/1995	
		5,399,346		Anderson et al.	03/21/1995	
		5,405,316		Magram	04/11/1995	
		5,468,221		Schöner	11/21/1995	
		5,478,807		Cronin et al.	12/26/1995	
		5,542,935		Unger et al.	08/06/1996	
		5,552,415		May	09/03/1996	
		5,643,207		Rise	07/01/1997	
		5,683,357		Magram	11/04/1997	
		5,728,061		Ahmed	03/17/1998	
		5,756,553		Iguchi et al.	05/26/1998	
		5,772,261		Magram	06/30/1998	
		5,846,220		Elsberry	12/08/1998	
		5,880,116		Vigo-Pelfrey	03/09/1999	
		5,895,378		Berenstein et al.	04/20/1999	
		6,056,725		Elsberry	05/02/2000	
		6,140,116		Dinsmore	10/31/2000	

RECEIVED
SEP 21 2001
TC 3700 MAIL ROOM

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date Considered

9/27/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.


³ Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

3 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible.

* Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → +



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. GOMS 0851-0051
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449B/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	09/872,698
		Filing Date	June 1, 2001
		First Named Inventor	Elsberry
		Group Art Unit	3763
		Examiner Name	Unknown
Sheet	2	of	2
		Attorney Docket Number	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Dorland's Illustrated Medical Dictionary, W.B. Saunders Company, p. 189.	
		Breitner, J.C.S. et al., "Inverse Association of Anti-Inflammatory Treatments and Alzheimer's Disease: Initial Results of a Co-Twin Control Study", <i>Neurology</i> , Vol. 44, pp. 227-232 (February, 1994).	
		Duong, Taihung et al., "Microtubule-association Proteins Tau and Amyloid P Component In Alzheimer's Disease", <i>Brain Research</i> , Vol. 608, pp. 74-86 (1993).	
		Eikelenboom, Piet et al., "Inflammatory Mechanisms In Alzheimer's Disease", <i>TiPs</i> , Vol. 15, pp. 447-450 (December 1994).	
		Forloni, Gianluigi et al., "Expression of Amyloid Precursor Protein mRNAs in Endothelial, Neuronal and Glial Cells: Modulation By Interleukin-1", <i>Molecular Brain Research</i> , Vol. 16, pp. 128-133 (1992).	
		Malmberg, A.B. et al., "Hyperalgesia Mediated by Spinal Glutamate or Substance P Receptor Blocked by Spinal Cyclooxygenase Inhibition", <i>Science</i> , Vol. 257, pp. 1276-1279 (August 28, 1992).	
		Meade, E.A. et al., "Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-inflammatory Drugs", <i>Vol. 268</i> , No. 9, pp.6610-6614 (March 25, 1993).	
		Mitchell, J.A. et al., "Selectivity of Nonsteroidal Antiinflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase", <i>Proceedings of the National Academy of Sciences</i> , Vol. 90, No. 24, pp. 1693-11697 (December 15, 1993).	
		Murphy, M., "The Molecular Pathogenesis of Alzheimer's Disease: Clinical Prospects", Vol. 340, pp. 1512-1515 (December 19/26, 1992).	
		Netland, E.E. et al., "Indomethacin Reverses β -amyloid Induced Gliosis", Department of Psychiatry and Human Behavior, Miriam Hospital and Brown University Medical School, 11 pgs. (Date Unknown).	
		Netland, E., "Neuropathological and Cognitive Impairment in an Animal Model of Alzheimer's Disease", Bachelor of Science with Distinction in the Neuroscience Concentration Thesis, Brown University, 55 pgs. (April 21, 1995).	
		Rich, J.B. et al., "Nonsteroidal Anti-inflammatory Drugs in Alzheimer's Disease", <i>Neurology</i> , Vol. 45, pp. 51-55 (January 1995).	
		Rogers, J. et al., "Clinical Trial of Indomethacin in Alzheimer's Disease", <i>Neurology</i> , Vol. 43, pp. 1609-1611 (August 1993).	
		Schnabel, J., "New Alzheimer's Therapy Suggested", <i>Science</i> , Vol. 260, pp. 1719-1720 (June 18, 1993).	
		Soukas, A.A., "Screening of a Possible Therapeutic Agent For Alzheimer's Disease", Biomedical Engineering Concentration of Brown University Thesis, 54 pgs. (April 28, 1995).	
		Tate, B.A. et al., "Continuous ICV Infusion of Synthetic β -amyloid Peptide: Potential Model For Amyloid Depositions", Dept. of Psychiatry and Human Behavior, The Miriam Hospital, Providence, Rhode Island 02906 (Date Unknown).	

RECEIVED

SEP 21
2000

Examiner Signature			Date Considered	9/27/01
-----------------------	--	--	--------------------	---------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation is attached.